Sign in

CIK 0001847367 · <br>Emerging growth company

ALUMIS INC.

Sign in to watch
Ticker
ALMS
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
FY end
Dec 31
Incorporated
DE
Entity type
operating
Phone
650-231-6625
Business address
280 EAST GRAND AVENUE, SOUTH SAN FRANCISCO, CA, 94080
Former names
FL2021-001, Inc.
  1. SCHEDULE 13G/A Stake Statement of Beneficial Ownership
  2. 4 Open-market sale Chief Financial Officer sold 794 shares at $6.52 ($5,177)
  3. 4 Open-market sale Chief Legal Officer sold 332 shares at $6.52 ($2,165)
  4. 4 Open-market sale Chief Business & Strategy Ofcr sold 652 shares at $6.52 ($4,251)
  5. 4 Open-market sale Chief Scientific Officer sold 629 shares at $6.52 ($4,101)
  6. 4 Open-market sale Chief Medical Officer sold 593 shares at $6.52 ($3,866)
  7. 4 Open-market sale Chief Development Officer sold 623 shares at $6.52 ($4,062)
  8. 4 Open-market buy Director bought 986,721 shares at an average $10.87 ($10,726,255)
  9. 8-K Event Other events
  10. 10-Q Report Quarterly Report
  11. 8-K Event Results of operations
  12. 8-K Event Other events
  13. SCHEDULE 13G Stake Statement of Beneficial Ownership
  14. 4 Open-market sale Chief Financial Officer sold 3,282 shares at $26.37 ($86,546)
  15. 4 Open-market sale Chief Legal Officer sold 1,364 shares at $26.37 ($35,969)
  16. 4 Open-market sale Chief Business & Strategy Ofcr sold 2,692 shares at $26.37 ($70,988)
  17. 4 Open-market sale Chief Scientific Officer sold 2,596 shares at $26.37 ($68,457)
  18. 4 Open-market sale Chief Medical Officer sold 2,447 shares at $26.37 ($64,527)
  19. 4 Open-market sale Chief Development Officer sold 2,572 shares at $26.37 ($67,824)
  20. SCHEDULE 13G Stake Statement of Beneficial Ownership

Page 1 of 13 · 248 filings